Blue Trust’s Xenon Pharmaceuticals XENE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-724
Closed -$43.7K – 2800
2026
Q2
$43.7K Sell
724
-21
-3% -$1.17K ﹤0.01% 1397
2026
Q1
$43.3K Hold
745
– – ﹤0.01% 1388
2025
Q4
$33.4K Buy
745
+717
+2,561% +$30.1K ﹤0.01% 1498
2025
Q3
$1.12K Hold
28
– – ﹤0.01% 2295
2025
Q2
$876 Sell
28
-242
-90% -$7.89K ﹤0.01% 2266
2025
Q1
$9.06K Buy
270
+22
+9% +$835 ﹤0.01% 1930
2024
Q4
$9.7K Sell
248
-760
-75% -$31.4K ﹤0.01% 1930
2024
Q3
$39.3K Buy
1,008
+641
+175% +$25.8K ﹤0.01% 1667
2024
Q2
$15.8K Buy
367
+340
+1,259% +$13.6K ﹤0.01% 1765
2024
Q1
$1.16K Sell
27
-95
-78% -$4.37K ﹤0.01% 1915
2023
Q4
$4K Buy
+122
New +$4.31K ﹤0.01% 1962
2023
Q1
– Sell
-29
Closed -$1K – 2667
2022
Q4
$1K Buy
+29
New +$1.06K ﹤0.01% 2161

Other funds holding XENE

Blue Trust's XENE Position: Q3 2026 in Review

Blue Trust sold out of Xenon Pharmaceuticals (XENE) in Q3 2026, closing a stake of 724 shares — an estimated $43.7K sold.

Blue Trust first reported a position in XENE in Q4 2022 and held it in 12 quarters. The position peaked at $43.7K in Q2 2026. 196 funds tracked by Wall St. Rank hold XENE as of Q3 2026.

  • Blue Trust reported no remaining Xenon Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Blue Trust sold 724 Xenon Pharmaceuticals shares in Q3 2026, an estimated $43.7K.
  • Blue Trust first reported a position in Xenon Pharmaceuticals in Q4 2022 and held it in 12 quarters.
  • Blue Trust's Xenon Pharmaceuticals position peaked at $43.7K in Q2 2026.
  • 196 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2026.

Based on Blue Trust's 13F filing for Q3 2026, filed 15 Oct 2026.